AMANINDER GREWAL: Open Payments
NPI 1467166355 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$399 in 17 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $1,772 · 2025 $399
Food & beverage: $399
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 2 | $109 |
| Alkermes, Inc. | 3 | $49 |
| Lundbeck LLC | 2 | $48 |
| Janssen Pharmaceuticals, Inc | 2 | $48 |
| Vanda Pharmaceuticals Inc. | 2 | $38 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $18 |
| Neurocrine BioSciences, Inc. | 1 | $16 |
Products named: COBENFY, ARISTADA, REXULTI, HETLIOZ, INVEGA SUSTENNA, ABILIFY MAINTENA, SPRAVATO, Jornay PM.
Industry payments across NY — which companies pay providers there.
